Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.18 EUR | -0.91% | -1.80% | -10.84% |
Apr. 30 | BIO-UV Group S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 20 | Bio-UV: partnership with U.S.-based Pinnacle Ozone | CF |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 24.92 | 27.43 | 69.53 | 52.95 | 47.1 | 24.75 |
Enterprise Value (EV) 1 | 25.66 | 38.77 | 70.62 | 73.11 | 74.27 | 50.3 |
P/E ratio | 538 x | -61.2 x | 98.6 x | 78.6 x | 19.6 x | 199 x |
Yield | - | - | - | - | 0.84% | - |
Capitalization / Revenue | 1.9 x | 1.32 x | 2.11 x | 1.54 x | 0.92 x | 0.59 x |
EV / Revenue | 1.96 x | 1.86 x | 2.14 x | 2.12 x | 1.45 x | 1.19 x |
EV / EBITDA | 103 x | -626 x | 41.3 x | 53 x | 16.2 x | 19.5 x |
EV / FCF | -6.19 x | -9.81 x | -19 x | 15.4 x | -8.36 x | 11 x |
FCF Yield | -16.2% | -10.2% | -5.27% | 6.5% | -12% | 9.08% |
Price to Book | 1.49 x | 1.71 x | 2.27 x | 1.74 x | 1.46 x | 0.77 x |
Nbr of stocks (in thousands) | 7,838 | 7,838 | 10,347 | 10,105 | 10,097 | 10,125 |
Reference price 2 | 3.180 | 3.500 | 6.720 | 5.240 | 4.665 | 2.445 |
Announcement Date | 4/30/19 | 5/5/20 | 5/3/21 | 4/29/22 | 4/4/23 | 4/30/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 13.1 | 20.82 | 32.97 | 34.49 | 51.29 | 42.12 |
EBITDA 1 | 0.2493 | -0.0619 | 1.712 | 1.38 | 4.575 | 2.586 |
EBIT 1 | 0.0148 | -0.3498 | 1.399 | 0.9976 | 4.132 | 2.298 |
Operating Margin | 0.11% | -1.68% | 4.24% | 2.89% | 8.06% | 5.46% |
Earnings before Tax (EBT) 1 | -0.197 | -0.777 | 0.5535 | 0.6313 | 2.995 | 0.0155 |
Net income 1 | 0.0463 | -0.4481 | 0.5839 | 0.6894 | 2.418 | 0.1249 |
Net margin | 0.35% | -2.15% | 1.77% | 2% | 4.71% | 0.3% |
EPS 2 | 0.005908 | -0.0572 | 0.0681 | 0.0666 | 0.2380 | 0.0123 |
Free Cash Flow 1 | -4.146 | -3.951 | -3.723 | 4.753 | -8.888 | 4.567 |
FCF margin | -31.65% | -18.98% | -11.29% | 13.78% | -17.33% | 10.84% |
FCF Conversion (EBITDA) | - | - | - | 344.49% | - | 176.61% |
FCF Conversion (Net income) | - | - | - | 689.43% | - | 3,656.64% |
Dividend per Share | - | - | - | - | 0.0390 | - |
Announcement Date | 4/30/19 | 5/5/20 | 5/3/21 | 4/29/22 | 4/4/23 | 4/30/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.73 | 11.3 | 1.09 | 20.2 | 27.2 | 25.5 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.941 x | -183 x | 0.6342 x | 14.61 x | 5.939 x | 9.878 x |
Free Cash Flow 1 | -4.15 | -3.95 | -3.72 | 4.75 | -8.89 | 4.57 |
ROE (net income / shareholders' equity) | 0.41% | -2.74% | 2.53% | 2.27% | 7.67% | 0.39% |
ROA (Net income/ Total Assets) | 0.04% | -0.68% | 1.98% | 0.94% | 3.33% | 1.97% |
Assets 1 | 116.4 | 66.3 | 29.44 | 73.55 | 72.67 | 6.325 |
Book Value Per Share 2 | 2.140 | 2.040 | 2.960 | 3.020 | 3.190 | 3.170 |
Cash Flow per Share 2 | 0.1100 | 0.1500 | 1.230 | 1.010 | 0.2000 | 0.2700 |
Capex 1 | 1.97 | 1.91 | 3.02 | 2.73 | 2.22 | 1.96 |
Capex / Sales | 15.04% | 9.17% | 9.15% | 7.91% | 4.33% | 4.66% |
Announcement Date | 4/30/19 | 5/5/20 | 5/3/21 | 4/29/22 | 4/4/23 | 4/30/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.84% | 23.98M | |
+4.24% | 150B | |
+25.29% | 138B | |
+31.79% | 127B | |
+12.46% | 62.62B | |
+0.46% | 38.34B | |
+91.09% | 34.36B | |
+14.31% | 32.31B | |
+23.44% | 30.96B | |
-14.95% | 30.1B |
- Stock Market
- Equities
- ALTUV Stock
- Financials BIO-UV Group